This paper was presented by Drs Carel Le Roux, Oren Steen, Kathryn J. Lucas, Elena Startseva, Anna Unseld, Anita M. Hennige from Dublin, Ireland, Toronto,

When a patient’s therapeutic objectives are not met, therapeutic inertia is the failure to initiate, intensify, or sometimes de-intensify therapy. It is a frequent issue

In November 2022, the U.S. Food and Drug Administration approved teplizumab, a CD3- directed monoclonal antibody and the first drug to be approved for the

In a new feature at the 83 Scientific Sessions, six diabetes innovators will have the opportunity to present their ideas to a panel of potential

Genome-wide association studies (GWAS) and polygenic risk scores (PRS) are two significant concepts in the field of genetics that have demonstrated promise as new tools

“First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention,Especially for Those Living with Diabetes” Today, a new study revealed information

As part of the session “Efficacy. Engagement, and Sustainability of Dietary Management Options in Type 2 Diabetes – Time for a Reappraisal?” This Paper Was

As part of the session “Efficacy. Engagement, and Sustainability of Dietary Management Options in Type 2 Diabetes – Time for a Reappraisal?” This Paper Was

As part of the session “Real-World Hypoglycaemia in Older Adults with Diabetes” This Paper Was Presented By Drs Emily Tang, Ilana Peterson, Christine Board, Richard

As part of the session “Real-World Hypoglycaemia in Older Adults with Diabetes” This Paper Was Presented By Drs Gemma A. Lewis, Janet Cardwell, Sumudu Bujawansa,